European Journal of Oncology Nursing
Volume 13, Issue 1 , Pages 49-59 , February 2009

Docetaxel-related side effects and their management

  • Jackie Baker

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Gastrointestinal Medical Oncology, Faculty Center Unit #426 FC10.3007, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 713 745 3917; fax: +1 713 745 7500.
    • ,
  • Jaffer Ajani

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    • ,
  • Florian Scotté

      Affiliations

    • Oncology Department, Hospital Européen Georges Pompidou, 20 rue Leblanc, Paris 75015, France
    • ,
  • Dorte Winther

      Affiliations

    • Section of Clinical Research, Department of Oncology, Norrebrogade 44, Aarhus C 8000, Denmark
    • ,
  • Miguel Martin

      Affiliations

    • Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid 28040, Spain
    • ,
  • Matti S. Aapro

      Affiliations

    • IMO Clinique de Genolier, 1 route du Muids, Genolier 1272, Switzerland
    • ,
  • Gunter von Minckwitz

      Affiliations

    • GBG Forschungs GmbH and University Women's Hospital Frankfurt, Schleussnerstrasse 42, Neu-Isenburg 63263, Gunter, Germany

References 

  1. Aapro M. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group. Semin. Oncol. 1998;25:7–11
  2. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur. J. Cancer. 2006;42:2433–2453
  3. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J. Clin. Oncol. 2007;25:3205–3209
  4. Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann. Oncol. 2007;18:168–172
  5. Apfel SC. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. Cancer Invest. 2000;18:564–573
  6. Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004;15:581–585
  7. Barton DL, Soori GS, Bauer B, Sloan J, Johnson PA, Figueras C, et al. A pilot, multi-dose, placebo-controlled evaluation of American ginseng (Panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA. J. Clin. Oncol. 2007;25(18S):9001
  8. Belani C. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Semin. Oncol. 2001;28:10–14
  9. Brain EGC, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard J-C, et al. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA. 2005;293:2367–2371
  10. Bremer CT, Monahan BP. Necrotixing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned. Curr. Gastroenterol. Rep. 2006;8:333–341
  11. Camps C, Massuti B, Jiménez A, Maestu I, Gómez RG, Isla D, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish lung cancer group trial. Ann. Oncol. 2006;17:467–472
  12. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2002;20:3478–3483
  13. Chan A. Taxotere-induced febrile neutropenia management. Hospital management. Spring. 2007;31–36
  14. Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11:19–24
  15. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 1999;17:2341–2354
  16. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J. Clin. Oncol. 2007;25:4396–4404
  17. Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur. J. Cancer. 2005;41:1117–1126
  18. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol. Oncol. 2005;96:824–829
  19. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nisticò C, et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am. J. Clin. Oncol. 2000;23:132–139
  20. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J. Clin. Oncol. 2000;18:2354–2362
  21. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003;21:3016–3024
  22. Gafter-Gvili A, Fraser A, Paul M, van de Wetering M, Kremer L, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2005;19:CD004386
  23. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist. 2004;9:538–545
  24. Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J. Clin. Oncol. 2006;Published online ahead of print on October 10
  25. Heim ME, v d Malsburg ML, Niklas A. Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue. Onkologie. 2007;30:429–434
  26. Hilkens PH, Verweij J, Stoter G, Vecht ChJ, van Putten WLJ, van den Bent MJ. Peripheral neurotoxicity induced by docetaxel. Neurology. 1996;46:104–108
  27. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). Ann. Oncol. 1997;8:187–190
  28. Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL, van den Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br. J. Cancer. 1997;75:417–422
  29. Hong J, Park SH, Choi SJ, Lee SH, Lee KC, Lee JI, et al. Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. Jpn. J. Clin. Oncol. 2007;37:424–428
  30. Hurria A, Jones S, Olsen S, Murawsky M, Tsai K-T, Alakl M, et al. Safety profile of docetaxel in patients >65 years of age with metastatic breast cancer: analysis of four phase III studies. Ann. Oncol. 2004;15(Suppl. 3):iii47;(abstr 176P)
  31. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke-Michaud L, Valero V, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000;355:281–283
  32. Katori H, Tsukuda M. Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Clin. Oncol. (R Coll. Radiol.). 2005;17:148–152
  33. Kohli S, Fisher SG, Tra Y, Wesnes K, Morrow GR. The cognitive effects of modafinil in breast cancer survivors: a randomised clinical trial. J. Clin. Oncol. 2007;25(18S):9004
  34. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J. Clin. Oncol. 2007;25:3158–3167
  35. Kuroi K, Bando H, Saji S, Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer. 2003;10:10–14
  36. Lichtman SM, Wildiers H, Chatelut E, Steer C, Budman D, Morrison VA, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literature. J. Clin. Oncol. 2007;25:1832–1843
  37. Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2007;2:306–311
  38. Luctkar-Flude MF, Groll DL, Tranmer JE, Woodend K. Fatigue and physical activity in older adults with cancer: a systematic review of the literature. Cancer Nurs. 2007;30:E35–E45
  39. Lynch TJ. Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin. Oncol. 2001;28:5–9
  40. Markman M. Managing taxane toxicities. Support. Care Cancer. 2003;11:144–147
  41. Marrs J, Newton S. Chemotherapy-induced nail changes: an unsightly nuisance. Clin. J. Oncol. Nurs. 2004;8:527–528
  42. Martin M, Lluch A, Segui MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann. Oncol. 2006;17:1205–1212
  43. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 2005;23:4265–4274
  44. Massacesi C, Marcucci F, Rocchi MB, Mazzanti P, Pilone A, Bonsignori M. Factors predicting docetaxel-related toxicity: experience at a single institution. J. Chemother. 2004;16:86–93
  45. McKeage K, Keam SJ. Docetaxel in hormone-refractory metastatic prostate cancer. Drugs. 2005;65:2287–2294discussion: 2295–2297
  46. Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?. J. Clin. Oncol. 2004;22:2901–2908
  47. Monga U, Garber SL, Thornby J, Vallbona C, Kerrigan AJ, Monga TN, et al. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Arch. Phys. Med. Rehabil. 2007;88:1416–1422
  48. Montoya ME, Markowitz AB, Klementich F, Palacio D. Docetaxel and fluid retention: use of single-dose dexamethasone. ASCO. 2007;abst 19635
  49. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J. Clin. Oncol. 2003;21:968–975
  50. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002;20:2812–2823
  51. Pavithran K, Dovalc D. Nail changes due to docetaxel. Br. J. Dermatol. 2002;146:709
  52. Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJ. Teams: communication in multidisciplinary care. Oncologist. 2006;11:520–526
  53. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J. Clin. Oncol. 1997;15:3149–3155
  54. Poikonen P, Sjöström J, Klaar S, Nittby LT, Sigurdsson H, Madsen EL, et al. Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel. Acta Oncol. 2004;43:190–195
  55. Pronk LC, Hilkens PH, van den Bent MJ, van Putten WL, Stoter G, Verweij J. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs. 1998;9:759–764
  56. Pujol JL, Paul S, Chouaki N, Peterson P, Moore P, Berry DA, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J. Thorac. Oncol. 2007;2:397–401
  57. Remenar E, Van Herpen C, Lluch JG, Stewart S, Gorlia T, Degardin M, et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971. ASCO. 2006;abstract 5516
  58. Taxotere 20mg and 80mg concentrate and solvent for infusion: summary of product characteristics. November 2007;
  59. Schwartz J, Domchek SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann. Oncol. 2005;16:247–252
  60. Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J. Clin. Oncol. 2005;23:4424–4429
  61. Scotté F, Banu E, Medioni J, Levy E, Ebenezar C, Marsan S, et al. Frozen sock use in the prevention of docetaxel-induced nails and skin toxicities: Results of a case-control study. ASCO Annual Meeting Proceedings Part 1 J. Clin. Oncol. 2007;25(18S):9059
  62. Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J. Clin. Oncol. 1998;16:3426–3432
  63. Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst. Rev. 2007;(4):Art. No.: CD005247
  64. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000;18:2095–2103
  65. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin. Oncol. 2001;28:4–9
  66. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 2006;24:3187–3205
  67. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann. Oncol. 1997;8:569–573
  68. Stanford BL, Shah SR, Ballard EE, Jumper CA, Rabinowitz I, Dowell JE, et al. A randomized trial assessing the utility of a test-dose program with taxanes. Curr. Med. Res. Opin. 2005;21:1611–1616
  69. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004;351:1502–1512
  70. ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J. Clin. Oncol. 2005;23:1070–1077
  71. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol. 2006;24:4991–4997
  72. van Poppel H. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can. J. Urol. 2005;12:81–85
  73. von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim±ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann. Oncol. 2007;Published online ahead of print on September 9
  74. Wanders J, Schrijvers D, Bruntsch U, Gore M, Verweij J, Hanauske A, et al. The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies. Proc. Am. Soc. Clin. Oncol. 1993;12:73;(abstr 94)
  75. Wasner G, Hilpert F, Baron R, Pfisterer J. Clinical picture: nail changes secondary to docetaxel. Lancet. 2001;357:910
  76. Winther D, Saunte DM, Knap M, Haahr V, Jensen AB. Nail changes due to docetaxel – a neglected side effect and nuisance for the patient. Support. Care Cancer. 2007;15:1191–1197
  77. Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001;24:767–779

PII: S1462-3889(08)00132-4

doi: 10.1016/j.ejon.2008.10.003

European Journal of Oncology Nursing
Volume 13, Issue 1 , Pages 49-59 , February 2009

Article Tools

* Image Usage & Resolution